PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$45.20

Daily low

$44.11

Price at open

$44.35

52 Week High

$60.60

52 Week Low

$27.00

Market cap

2.8B

Dividend yield

0.00%

Volume

649,134

Avg. volume

890,377

P/E ratio

58.49

Protagonist Therapeutics News